SRI, (founded by Stanford Univ. in 1946) is a leading  non profit research institute. Our focus for this meeting is (1) seeking seed and early stage investors for our 2 new start-ups – Radiotherapeutics and MCED diagnostics (2) out-licensing for an I/O Oncology asset at mid preclinical (with ODD) (3)  seek commercial partners in areas of cardiovascular, metabolic, oncology, I/O , CNS/BBB/neurology, musculoskeletal, inflammatory disease, chronic/rare diseases, precision medicine, 3D Printing, and animal health.

Our partnering is focused on a novel, first in class platform (FOX Three™)  for targeted intracellular delivery of bio-therapeutic cargos: nucleic acids, antibodies, or proteins. We have strong in-vivo data across a number of cell types.

As a non-profit institute, we rely on commercial partnerships to move our platforms and programs into the market through research collaborations and license/option deals.